{
    "nct_id": "NCT05907122",
    "official_title": "A Randomized, Double-blind Study Evaluating Pharmacokinetic Similarity of ABP 206 Compared With OPDIVOÂ® (Nivolumab) in Resected Stage III or Stage IV Melanoma Subjects in the Adjuvant Setting",
    "inclusion_criteria": "* At least 18 years of age\n* Completely removed melanoma by surgery performed within 12 weeks of randomization\n* Advanced Melanoma\n* Tumor tissue from the resected site of the disease must be available for biomarker analyses in order to be randomized\n* Subject has an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 99 Years",
    "exclusion_criteria": "* Previous anti-cancer treatment\n* Known hypersensitivity to monoclonal antibodies or to any of the excipients of the study drug\n* Ocular or uveal melanoma or history of carcinomatosis meningitis\n* History of auto-immune disease\n* Subject has medical conditions requiring systemic immunosuppression with either corticosteroids or other immunosuppressive medications within 14 days of the first dose of the investigational product\n\nOther protocol-defined inclusion/exclusion criteria apply",
    "miscellaneous_criteria": ""
}